Advanced therapy supply chains are undergoing a fundamental transformation as regulatory expectations and patient-centric risk considerations continue to intensify across the industry.
Adam Fox, Chief Quality and Regulatory Affairs Officer of Cryoport Systems, has outlined how organisations must rethink the way they design and scale supply chains for cell and gene therapies.
Fox argues that traditional supply chain models are no longer fit for purpose when applied to advanced therapies, where the stakes for patients and regulators alike are extraordinarily high.
The core challenge lies in protecting high-value, temperature-controlled biological materials across complex global distribution networks that span multiple jurisdictions and regulatory environments.
Cell and gene therapies present unique logistical vulnerabilities that conventional pharmaceutical supply chains were simply never built to accommodate or manage at scale.
Fox emphasises that quality infrastructure cannot be retrofitted onto an existing supply chain but must instead be embedded at the foundational level from the very beginning of a programme’s design.
End-to-end control strategies are becoming a defining feature of how leading organisations approach the movement of advanced therapy materials from manufacturing site to patient bedside.
Cryoport Systems positions itself as a trusted partner for organisations seeking to maintain both regulatory compliance and operational continuity across some of the world’s most demanding distribution networks.
The regulatory landscape surrounding advanced therapies has shifted considerably, with authorities now scrutinising supply chain integrity as closely as they examine manufacturing quality and clinical outcomes.
Organisations that treat supply chain management as a secondary concern risk falling short of expectations set by regulators who increasingly view logistics as an extension of the quality system itself.
Fox’s perspective reflects a broader industry shift in which supply chain excellence is no longer a competitive differentiator but rather a baseline requirement for bringing advanced therapies safely to patients.
The quality-driven playbook he describes demands rigorous documentation, real-time monitoring, and proactive risk management across every node of the distribution network without exception.